Latest Breaking News On - Prnewswire soligenix inc - Page 7 : comparemela.com

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

San diegoUnited statesNeal bhatiaChristopherj schaberBiomedical advanced researchWorld health organizationCompany psoriasisClinical dermatology at therapeutics researchPrnewswire soligenix incDevelopment authorityUs developmentOur public health solutionsDefense threat reduction agencyExchange commissionNational institute of allergyUs congress

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

Peptides for specific use in oral mucositis treatment adds to existing composition of matter claims PRINCETON, N.J., May 16, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical. | May 16, 2023

United kingdomUnited statesNew zealandChristopherj schaberB brett finlayRobert hancockEuropean patent officeNational institute of allergyDefense threat reduction agencyUs congressUniversity of british columbiaDevelopment authorityPrnewswire soligenix incBiomedical advanced researchUs developmentRegulatory agency

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSoligenix incUs congressBiomedical advanced researchDefense threat reduction agencyUs developmentExchange commissionDevelopment authorityPrnewswire soligenix incOur public health solutionsDrug administrationNational institute of allergyWhile the companyOffice of orphan products developmentChief executive officerSilk road therapeutics

Soligenix Announces Scheduling of Type A Meeting with the U S FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesChristopherj schaberUs congressUs developmentWhile the companyDrug administrationDevelopment authorityEuropean medicines agencyNational institute of allergyPrnewswire soligenix incSoligenix incDefense threat reduction agencyOur public health solutionsExchange commissionBiomedical advanced researchOutcome expected next

Soligenix Announces Pricing of $8 5 Million Public Offering

PRINCETON, N.J., May 5, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an. | May 5, 2023

New yorkUnited statesUs congressNational institute of allergyBiomedical advanced researchPrnewswire soligenix incDefense threat reduction agencyUs developmentDevelopment authorityOur public health solutionsSoligenix incA gp alliance global partnersExchange commissionAlliance global partnersPublic health solutionsNational institute